Follow up of phenylketonuria patients
- PMID: 22018725
- DOI: 10.1016/j.ymgme.2011.08.005
Follow up of phenylketonuria patients
Abstract
In recent years our understanding of the follow up policies for PKU has increased substantially. In particular, we now understand the importance of maintaining control of blood phenylalanine (phe) concentrations life-long to achieve the best long-term neuropsychological outcomes. The concordance with the follow up strategy remains a key challenge for the future, especially with respect to adolescents and young adults. The recent therapies could ease the burden of the dietary phe restriction for PKU patients and their families. The time may be right for revisiting the guidelines for follow up of PKU in order to address a number of important issues related to PKU management: promotion of breastfeeding to complementary feeding up to 2 years of age for prevention of early growth retardation and later overweight development, treatment advancements for metabolic control, blood phe and tyr variability, routine screening measures for nutritional biomarkers, neurocognitive and psychological assessments, bone pathology, understanding the challenges of compliance and transitioning into adulthood as an individual with PKU and addressing unmet needs in this population.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Outcomes beyond phenylalanine: an international perspective.Mol Genet Metab. 2010;99 Suppl 1:S79-85. doi: 10.1016/j.ymgme.2009.09.015. Mol Genet Metab. 2010. PMID: 20123476 Review.
-
Mental health and social functioning in early treated Phenylketonuria: the PKU-COBESO study.Mol Genet Metab. 2013;110 Suppl:S57-61. doi: 10.1016/j.ymgme.2013.10.011. Epub 2013 Oct 22. Mol Genet Metab. 2013. PMID: 24183792
-
Adult phenylketonuria outcome and management.Mol Genet Metab. 2011;104 Suppl:S26-30. doi: 10.1016/j.ymgme.2011.08.025. Epub 2011 Aug 26. Mol Genet Metab. 2011. PMID: 21944883 Review.
-
Long-term outcomes of blood phenylalanine concentrations in children with classical phenylketonuria.Mol Genet Metab. 2013 Apr;108(4):255-8. doi: 10.1016/j.ymgme.2013.01.007. Epub 2013 Jan 23. Mol Genet Metab. 2013. PMID: 23465864
-
Phenylketonuria Scientific Review Conference: state of the science and future research needs.Mol Genet Metab. 2014 Jun;112(2):87-122. doi: 10.1016/j.ymgme.2014.02.013. Epub 2014 Mar 6. Mol Genet Metab. 2014. PMID: 24667081
Cited by
-
Management of adult patients with phenylketonuria: survey results from 24 countries.Eur J Pediatr. 2015 Jan;174(1):119-27. doi: 10.1007/s00431-014-2458-4. Epub 2014 Dec 6. Eur J Pediatr. 2015. PMID: 25480112
-
Phenylketonuria from the perspectives of patients in Türkiye.Orphanet J Rare Dis. 2024 Feb 20;19(1):78. doi: 10.1186/s13023-024-03079-z. Orphanet J Rare Dis. 2024. PMID: 38378595 Free PMC article.
-
Long-Term Neurological Outcomes of Adult Patients with Phenylketonuria before and after Newborn Screening in Japan.Int J Neonatal Screen. 2021 Apr 14;7(2):21. doi: 10.3390/ijns7020021. Int J Neonatal Screen. 2021. PMID: 33919983 Free PMC article.
-
Phenylalanine hydroxylase misfolding and pharmacological chaperones.Curr Top Med Chem. 2012;12(22):2534-45. doi: 10.2174/1568026611212220008. Curr Top Med Chem. 2012. PMID: 23339306 Free PMC article. Review.
-
Development of an mRNA replacement therapy for phenylketonuria.Mol Ther Nucleic Acids. 2022 Feb 28;28:87-98. doi: 10.1016/j.omtn.2022.02.020. eCollection 2022 Jun 14. Mol Ther Nucleic Acids. 2022. PMID: 35356682 Free PMC article.
Publication types
MeSH terms
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Medical